Korro Bio (KRRO) AI Stock Analysis

• Market Cap: $101.05M
• Dividend Yield: N/A
• Average Volume (3M): 734.66K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.58
• Revenue Growth: N/A
• EPS Growth: 21.61%
• Country: US
• Employees: 112
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.92
• Shares Outstanding: 9,417,295
• 10 Day Avg. Volume: 1,808,258
• 30 Day Avg. Volume: 734,659
• PEG Ratio: 0.05
• Price to Book (P/B): 2.12
• Price to Sales (P/S): 149.54
• P/FCF Ratio: -4.36
• Enterprise Value/Market Cap: 1.28
• Enterprise Value/Revenue: 17.58
• Enterprise Value/Gross Profit: 17.58
• Enterprise Value/Ebitda: -1.47
• 1Y Price Target: $17.67
• Price Target Upside: 64.49% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 10
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 46 Neutral
• Price Target: $10.50 ▼(-2.23% Downside)

The score is primarily held back by very large operating losses and heavy ongoing cash burn, despite improving revenue. Technicals show a short-term rebound but remain weak versus longer-term averages and appear stretched. Corporate events are mixed, with promising KRRO-121 progress offset by trial termination, a paused major collaboration, and restructuring signals.

Positive Factors

Proprietary RNA-editing Platform (OPERA)

A proprietary OPERA RNA-editing platform is a durable competitive asset: it enables modular, programmable therapeutic approaches across multiple genetic and liver-targeted indications, supports repeated program nominations, and underpins long-term partnership and pipeline scaling opportunities.

Advancing Liver-Directed Pipeline

A planned regulatory filing for KRRO-121 in H2 2026 represents a structural pipeline maturation milestone. Regulatory progress can de-risk the program, improve partner/outsider confidence, and create an inflection point for future collaborations or milestone revenues that support long-term commercialization prospects.

Moderate Financial Leverage

Moderate leverage (D/E ~0.39) and stable total debt provide relative financial flexibility versus highly levered peers. This structural debt profile reduces immediate solvency risk, allowing the company to allocate limited resources to R&D and filings while managing refinancing or partnership approaches over coming quarters.

Negative Factors

High Cash Burn and Large Losses

Sustained large operating losses and negative cash flow relative to minimal revenue create lasting funding pressure. Continued reliance on external financing risks dilution, constrains simultaneous development of programs, and can force prioritization or delays that materially affect long-term pipeline execution and investor support.

Partner Pause and Trial Termination

Termination of a clinical trial and a 12-month pause with a major partner materially reduce external validation, milestone prospects, and near-term reimbursed activity. These structural setbacks slow development de-risking, increase self-funding needs, and heighten strategic uncertainty around program prioritization and timelines.

Workforce Cuts and C-suite Turnover

A large 34% headcount reduction and the CMO resignation are durable operational risks: while they extend runway, they can impair R&D throughput, clinical operations, and regulatory readiness. Loss of clinical leadership raises execution risk for filings and trials, potentially delaying key milestones.

Korro Bio Business Overview & Revenue Model

Company Description

Korro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. Korro Bio, Inc. is based in Cambridge, Massachusetts.

How the Company Makes Money

Korro Bio Financial Statement Overview

Summary

Revenue has improved (TTM ~$7.4M vs ~$2.3M in 2024), but the company remains deeply unprofitable (TTM operating loss ~-$94.5M; net loss ~-$88.4M) with significant cash burn (TTM operating cash flow ~-$68.4M; free cash flow ~-$70.2M). The balance sheet shows only moderate leverage (debt-to-equity ~0.39), but equity has declined materially (about $160.4M in 2024 to ~$99.0M TTM), increasing funding pressure.

Income Statement

TTM (Trailing-Twelve-Months) revenue improved to about $7.4M versus $2.3M in 2024, showing progress in top-line traction. However, profitability remains very weak: TTM operating loss (~-$94.5M) and net loss (~-$88.4M) are extremely large relative to revenue, with deeply negative operating and net margins. Overall, the income statement reflects early/clinical-stage economics with improving revenue but heavy ongoing loss intensity.

Balance Sheet

Leverage is moderate with TTM debt-to-equity around 0.39 and total debt roughly stable (~$44.7M), which supports financial flexibility versus more highly levered peers. That said, equity has declined materially (about $160.4M in 2024 to ~$99.0M TTM), reflecting continued losses and increasing balance-sheet pressure. Returns remain negative (TTM return on equity around -0.62), highlighting that the capital base is not currently generating shareholder value.

Cash Flow

Cash burn remains significant: TTM operating cash flow is about -$68.4M and free cash flow about -$70.2M, with free cash flow slightly worse versus the prior period (TTM free cash flow growth roughly -4.9%). Free cash flow is negative but broadly in line with the reported net loss (free cash flow to net income ~1.10), indicating losses are translating into real cash outflows. Overall cash generation is the key weakness, implying continued dependency on external funding if trends persist.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	7.37M	2.27M	0.00	0.00	14.07M	36.98M
Gross Profit	7.37M	2.27M	0.00	0.00	10.23M	35.40M
EBITDA	-88.44M	-88.34M	-80.90M	-56.49M	-80.07M	-24.90M
Net Income	-88.42M	-83.58M	-81.17M	-58.03M	-84.69M	-26.51M
Balance Sheet
Total Assets	161.55M	226.24M	221.66M	73.74M	185.36M	264.72M
Cash, Cash Equivalents and Short-Term Investments	93.48M	126.09M	166.15M	55.85M	130.71M	220.34M
Total Debt	44.67M	44.77M	33.21M	166.99M	45.60M	45.99M
Total Liabilities	62.52M	65.83M	51.75M	172.77M	54.53M	72.23M
Stockholders Equity	99.03M	160.41M	169.91M	-99.03M	130.82M	192.49M
Cash Flow
Free Cash Flow	-70.24M	-77.98M	-75.12M	-58.86M	-36.54M	-51.86M
Operating Cash Flow	-68.35M	-60.07M	-67.28M	-53.65M	-32.09M	-45.19M
Investing Cash Flow	26.31M	-123.35M	11.16M	11.06M	-39.50M	10.40M
Financing Cash Flow	1.24M	69.36M	187.76M	18.00K	115.94M	56.69M

Korro Bio Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 10.74
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KRRO, the sentiment is Neutral. The current price of 10.74 is above the 20-day moving average (MA) of 9.03, above the 50-day MA of 7.79, and below the 200-day MA of 19.31, indicating a neutral trend. The MACD of 0.10 indicates Negative momentum. The RSI at 61.18 is Neutral, neither overbought nor oversold. The STOCH value of 87.26 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for KRRO.

Korro Bio Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ANNX	56 Neutral	$963.89M	―	-83.98%	―	―	-35.62%
DSGN	55 Neutral	$595.84M	-8.92	-29.83%	―	―	-40.26%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ASMB	49 Neutral	$432.44M	-5.73	-36.94%	―	31.30%	32.79%
FDMT	47 Neutral	$455.37M	-2.16	-45.38%	―	―	―
KRRO	46 Neutral	$101.05M	-1.14	-63.46%	―	―	21.61%
AURA	42 Neutral	$354.98M	-2.94	-64.26%	―	―	-11.41%

Korro Bio Corporate Events

Korro Bio Showcases KRRO-121 RNA Editing Program Progress

On January 27, 2026, Korro Bio, Inc. held a virtual Analyst Day where management presented KRRO-121, a GalNAc-conjugated antisense oligonucleotide designed to edit glutamine synthetase (GS) mRNA in the liver, creating a more stable GS variant to enhance ammonia clearance. The company highlighted preclinical data showing that KRRO-121 stabilized GS and improved ammonia control in human cell models of urea cycle disorders, underscoring its potential as a first-in-class, pan-urea cycle disorder treatment that could relax dietary restrictions and address broader ammonia-driven conditions such as hepatic encephalopathy; Korro also indicated plans to submit a regulatory filing in the second half of 2026 to enable a first-in-human trial, marking a key step in advancing its RNA-editing platform and expanding its presence in the genetic medicines space.

The most recent analyst rating on (KRRO) stock is a Hold with a $10.50 price target. To see the full list of analyst forecasts on Korro Bio stock, see the KRRO Stock Forecast page.

Korro Bio Updates Pipeline, Terminates KRRO-110 REWRITE Trial

On January 15, 2026, Korro Bio, Inc. updated its corporate presentation for investors and analysts, outlining a pipeline that includes KRRO-121 for hyperammonemia progressing toward a planned regulatory filing in the second half of 2026, an AATD GalNAc-conjugated development candidate expected to be nominated in the first half of 2026, and a liver-focused longevity program and TDP43-targeted ALS program that leverage RNA-editing approaches. The company disclosed it has terminated the REWRITE clinical trial for KRRO-110 in AATD and that its collaboration with Novo Nordisk entered a 12‑month pause in November 2025, signaling a strategic pivot toward newer RNA-editing assets that may reshape its near-term development priorities and investor focus.

The most recent analyst rating on (KRRO) stock is a Sell with a $8.50 price target. To see the full list of analyst forecasts on Korro Bio stock, see the KRRO Stock Forecast page.

Korro Bio Enhances Executive Compensation and Retention Incentives

On December 15, 2025, Korro Bio, Inc. amended and restated the employment agreement of executive Jeffrey Cerio, keeping most terms consistent with his August 28, 2024 contract but raising his annual base salary to $425,000 and enhancing his severance protections, including longer payout periods in the event of termination without cause or resignation for good reason, particularly following a change in control. As part of a broader employee appreciation and retention effort, Korro also granted Cerio a $100,000 cash bonus, payable in two tranches in late 2025 and mid-2026 contingent on continued service, and awarded him 41,902 restricted stock units vesting in mid-2026 and late 2026, underscoring the company’s focus on retaining key leadership through more robust cash and equity incentives.

The most recent analyst rating on (KRRO) stock is a Hold with a $81.00 price target. To see the full list of analyst forecasts on Korro Bio stock, see the KRRO Stock Forecast page.

Korro Bio Pauses Novo Nordisk Collaboration Amid Restructuring

On November 11, 2025, Korro Bio and Novo Nordisk agreed to pause their research collaboration and license agreement for 12 months, allowing Korro to wind down its activities during this period with Novo Nordisk reimbursing certain costs. This strategic move is part of Korro’s broader restructuring efforts, which include a 34% workforce reduction to extend its cash runway into the second half of 2027. Additionally, Korro announced the resignation of its Chief Medical Officer, Dr. Olukemi A. Olugemo, effective November 12, 2025, who will continue as an advisor for three months post-resignation. These changes are aimed at refocusing resources on advancing Korro’s RNA editing platform and GalNAc-conjugated programs targeting liver diseases.

The most recent analyst rating on (KRRO) stock is a Buy with a $93.00 price target. To see the full list of analyst forecasts on Korro Bio stock, see the KRRO Stock Forecast page.